Event

COVID-19: State of the art – DRAGON IMI project

29 April, 2021 Online

Information: ERS Statement on COVID-19 and upcoming ERS events

A full-day virtual event dedicated to COVID-19, where top level faculty will share the latest advances, data and best practices relating to SARS-CoV-2 and COVID-19.

This event brings together world-leaders tackling COVD-19 and how different digital approaches to big data will help us to defeat the pandemic”Professor Christopher Brightling, event co-chair

Target audience:

  • DRAGON consortium members
  • Clinicians, researchers, nurses, physiotherapists, and other healthcare workers
  • Epidemiologists
  • Data scientists
  • Public health representatives
  • Radiologists
  • Patient organisations

Background

The DRAGON project is coordinated by the University of Maastricht with Radiomics as the Project Lead, and partners comprised of high-tech small and medium-sized enterprises (SMEs), academic research institutes, biotechnology and pharmacological partners, and ELF and ERS. Funded by the Innovative Medicines Initiative (IMI), it will use AI and machine learning to deliver a patient-centred decision support system that will enable stakeholders to participate in the development of rapid precise diagnosis and prognosis.

“The application of digital imaging together with clinical data to inform clinical decisions through artificial intelligence is very exciting.  The DRAGON project offers to do this as part of our response to the pandemic.” Professor Christopher Brightling, event co-chair

CME credits

This event has been granted 8 CME credits by the European Board for Accreditation in Pneumology (EBAP). The number of credits that you will receive will correspond to the time you spend watching the event while it livestreams. To receive CME and attendance certificates, your participation of at least 60 minutes during the live event is required.

The event, chaired by Professors Christopher Brightling and Eva Polverino, consists of live presentations which discuss the disease, from basic science to the post-care of COVID-19 patients.

As part of the DRAGON project, an emphasis is placed on the increasing role of big data in diagnosing and prognosing the COVID disease.

“This event will include cutting edge science and the latest clinical advances using big data approaches to battle against Covid-19” Professor Christopher Brightling, event co-chair

The programme will consist of the following sessions:

  • COVID-19 recapitulation
  • Epidemiology and prevention
  • Management
  • Patient view
  • Impact in adult patients with premorbid disease and in children
  • Long COVID
  • Big data, machine learning and AI for COVID-19
  • Application of big data technology for COVID-19

View the full, detailed programme below:

Access the virtual programme

ERS members€20
Non-ERS members€20

 

Registration grants access to the full programme as well as to all recorded materials.

Terms and conditions

Registering for someone else? Contact registration@ersnet.org

Chairs

Christopher Brightling - profile image
Christopher Brightling
United Kingdom

Professor Christopher Brightling is Senior Investigator at the National Institute for Health Research (NIHR), Clinical Professor in Respiratory Medicine, Chair of the ERS Science Council and founding Director of the ERS Clinical Research Collaborations. His research focuses on improving the clinical management, and understanding the immunopathogenesis of asthma, chronic cough and COPD.

He has published over 370 peer-reviewed articles, has an h-index of 95, and is a member of the American College of Chest Physicians’ Cough Guidelines, the British Thoracic Society, the American Thoracic Society/European Respiratory Society Severe Asthma guidelines and the scientific committee for the Global INitiative for Asthma - GINA.


Declaration of Interests

Declaration of Interests of Christopher E. Brightling

Annual Declaration of Interest 2020-2021

1 - Personal interests

Regular Paid Consultancy Work
CompanyAreaProductAmount of funds received*
Novartis, Chiesi, 4DPharmaAirways DiseaseNot product specificD
Sanofi/Regeneron, TEVAAirways DiseaseNot product specificD
GSK, Genentech/RocheAirways DiseaseNot product specificD
BI, Mologic, Gossamer, AZ/MedImmuneAirways DiseaseNot product SpecificD
Shionogi, CSL BehringAirways DiseaseNot product specificC
Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Eva Polverino - profile image
Eva Polverino
Spain

Dr Eva Polverino is a pulmonology expert in respiratory infections. She is Senior Researcher at the Vall D’Hebron Institute of Research (VHIR) in Barcelona, Spain and Head of ERS Assembly 10; ‘Respiratory Infections’.

Dr Polverino graduated from the medical School of the Second University of Naples (SUN) in 1999 and obtained her doctorate from the University of Pisa in 2002. She also holds a master’s degree in the management of Clinical Units from the University of Murcia.


Declaration of Interests

Declaration of Interests of Eva Polverino

Annual Declaration of Interest 2020-2021

1 - Personal interests

Regular Paid Consultancy Work
CompanyAreaProductAmount of funds received*
Chiesicystic fibrosis and bronchiectasishypertonic saline and nebulized levofloxacinA
Zambonbronchiectasisnebulized colistinB
Insmedbronchiectasisinhaled amikacinC
Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

CompanyNature of SupportAmount of funds received*
Grifolsresearch grantD

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000

Organising committee

Stefano Aliberti - profile image
Stefano Aliberti
Italy

Stefano Aliberti is Professor of Respiratory Medicine at the University of Milan, Italy, a member of the ERS Clinical Research Collaboration working group, and a former ERS Curriculum Development Director, who has also collaborated in the writing of the ERS Guidelines for the management of adult bronchiectasis.

He graduated with honours from the University of Milan’s School of Medicine in 2003, before completing a Fellowship in Pulmonary and Critical Care Medicine at the university’s Institute of Respiratory Diseases. After that, he completed a Clinical Research Fellowship in Pulmonary Medicine at his alma mater, and from 2006 to 2007, he was a clinical research fellow at the Division of Infectious Diseases of the Internal Medicine Department of the University of Louisville in the United States.

Professor Aliberti is the co-author of more than 50 scientific articles and book chapters, and has delivered dozens of lectures at national and international events as well as courses at university and master’s degree level. Because of his scientific work, Professor Aliberti was laureated with the 2007 ERS Young Researcher Award.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
James Chalmers - profile image
James Chalmers
United Kingdom

James Chalmers is Professor of Respiratory Medicine at the University of Dundee and a consultant physician. Graduating from the University of Glasgow’s School of Medicine, he has since gone on to obtain a doctorate from the University of Edinburgh,
and is now a member of Edinburgh’s Royal College of Physicians.

He has published more than 200 peer reviewed papers, chairs the European Bronchiectasis Registry, and serves regularly as a reviewer for each of the major respiratory medicine journals (American Journal of Respiratory and Critical Care Medicine, Thorax, European Respiratory Journal, Chest, Respiratory Medicine).

His research operates at both translating basic discoveries into therapies, and translating therapies into clinical practice, and has deliberately focussed on areas of perceived need in respiratory medicine, with high morbidity and mortality but limited investment in research.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Nina C. Flerin - profile image
Nina C. Flerin
Belgium
Grant Manager at Radiomics

Nina C. Flerin is a biomedical scientist with knowledge across a range of therapeutic areas, including HIV, oncology and immunity, immunotherapies and immunometabolism.

Her extensive experience in scientific writing has resulted in three primary research publications, two reviews and numerous research abstracts, conference presentations, grant applications and regulatory documents.

She is passionate about science and the sharing of scientific discoveries, with the ultimate goal of benefitting patients in the clinic.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Marko Topalović - profile image
Marko Topalović
Belgium
CEO of ArtiQ

Marko Topalović PhD is a CEO of ArtiQ (Leuven, Belgium); a company that aims to empower medical professionals with artificial intelligence to accurately and timely diagnose, treat and monitor patients with lung diseases.

Formerly, as a postdoctoral researcher in the University Hospital in Leuven (Belgium), Marko worked on inventing algorithms for assessing lung disease. He obtained a PhD degree on the topic “Artificial intelligence for pulmonary function tests” at the KU Leuven.

His scientific work has contributed to many peer-reviewed publications and numerous conference presentations. Moreover, he received several international awards.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Scott Wagers - profile image
Scott Wagers
Belgium
Founder and CEO of BioSci Consulting

Dr Scott Wagers trained as a respiratory and critical care physician and researcher, and brings more than 20 years’ experience in the life sciences, with more than 10,000 hours of experience as a moderator of dialogue in cognitively diverse teams.

As the founder and CEO of BioSci Consulting, he has had a pivotal role in several European based collaborative research projects (U-BIOPRED, AirPROM, COPD MAP, eTRIKS, ERS Research Agency, AIMS-2-Trials).

His main focus is on bringing innovative companies together with stakeholders and diverse disciplines to develop and deliver collaborative projects that will help change the future of medicine.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Janne Vignero - profile image
Janne Vignero
Belgium

Janne Vignero is a medical physicist and obtained a PhD in X-ray physics in 2018. Currently, she works as a post-doctoral researcher at the Radiology department of the university hospital of Leuven, Belgium, where she tries to make the bridge between technical research and clinic. With a background in physics and experience in medical imaging, she collaborates with radiologists to bring deep learning and data science into clinical practice.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000
Ruud van der Made - profile image
Ruud van der Made
Netherlands
Patient

Ruud van der Made is a member of the COVID-19 Patient Advisory Group and a COVID-19 patient. He cares for his wife (also having survived COVID-19) who has Lymphangioleiomyomatosis.


Declaration of Interests

Declaration of Interests of

1 - Personal interests

Regular Paid Consultancy Work

None

Personal Benefits

None

Personal Travel Grants or expenses for conferences etc.

None

Shares in any Relevant Companies (excluding mutual funds)

None

2 - Non-Personal interests

None

3 - Other Interests that may be seen as potential conflicts

None

4 - Tobacco-Industry related Conflicts of Interests

No. I declare that I have not been full or part time employee of, paid consultant or advisor to /received a grant from the tobacco industry at any time after 1.1.2000, for any project or programme.


*Funds Code Legend
ABCD
less than € 1'000€ 1001 - € 5'000€ 5'001 - € 20'000more than € 20'000

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 101005122. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.